Todd Harris Sells 8,210 Shares of Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) Stock

Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) insider Todd Harris sold 8,210 shares of the firm’s stock in a transaction dated Monday, April 9th. The shares were sold at an average price of $20.00, for a total value of $164,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Todd Harris also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Monday, March 19th, Todd Harris sold 5,876 shares of Sienna Biopharmaceuticals stock. The shares were sold at an average price of $20.00, for a total value of $117,520.00.
  • On Friday, March 9th, Todd Harris sold 20,672 shares of Sienna Biopharmaceuticals stock. The shares were sold at an average price of $20.03, for a total value of $414,060.16.

Sienna Biopharmaceuticals stock traded up $0.29 during trading hours on Monday, hitting $19.59. The stock had a trading volume of 104,342 shares, compared to its average volume of 94,946. The company has a market capitalization of $400.15 and a PE ratio of -3.77. Sienna Biopharmaceuticals Inc has a one year low of $13.37 and a one year high of $29.25.

Sienna Biopharmaceuticals (NASDAQ:SNNA) last posted its earnings results on Thursday, March 15th. The company reported ($0.56) EPS for the quarter. equities research analysts forecast that Sienna Biopharmaceuticals Inc will post -2.91 EPS for the current year.

A number of institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its position in Sienna Biopharmaceuticals by 13.9% in the fourth quarter. Geode Capital Management LLC now owns 45,153 shares of the company’s stock valued at $819,000 after purchasing an additional 5,499 shares during the last quarter. Deutsche Bank AG raised its position in Sienna Biopharmaceuticals by 139.8% in the fourth quarter. Deutsche Bank AG now owns 11,338 shares of the company’s stock valued at $205,000 after purchasing an additional 6,609 shares during the last quarter. California State Teachers Retirement System bought a new position in Sienna Biopharmaceuticals in the third quarter valued at about $182,000. Goldman Sachs Group Inc. bought a new position in shares of Sienna Biopharmaceuticals during the fourth quarter worth about $195,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Sienna Biopharmaceuticals during the third quarter worth about $274,000. Hedge funds and other institutional investors own 41.68% of the company’s stock.

SNNA has been the topic of several research analyst reports. ValuEngine raised Sienna Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Zacks Investment Research lowered Sienna Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 31st. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $32.25.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Macon Daily and is the sole property of of Macon Daily. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://macondaily.com/2018/04/16/sienna-biopharmaceuticals-inc-snna-insider-todd-harris-sells-8210-shares-updated.html.

About Sienna Biopharmaceuticals

Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.

Insider Buying and Selling by Quarter for Sienna Biopharmaceuticals (NASDAQ:SNNA)

Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply